Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
It’s clearly fake - they’ve opened up about five “class actions” in the last fortnight. Forget about it.
- Voleon reduced its position by 0.11% (now 0.55%)
- Citadel increased its position by 0.02% (now 0.5%)
I’ve been building my position over the past few weeks - happy to sit and watch now.
Im very relaxed about the situation:
1. Gains in the market in the cyclicals and badly hit leisure / retail sectors have dragged some investment away, as the gains level off we will see some more inflows here.
2. Short position is closing - if I’m a PI waiting in the wings the short position may have put me off, it’s winding down is encouraging.
3. We clearly have strong support at 88p, again investors worrying about a gap full will start to see it’s a strong point of resistance.
4. The closer we edge toward NASDAQ listing the more PIs will want to be part of that story, once momentum starts we will move up.
5. Sentiment in the Microbiome sector seems to be shifting, as called out in the article in Nature this is moving away from being vapourware to being a real clinically useful science. Success for any of our competitors is good for everyone as we are still priced as fairy dust.
Shares are inherently forward looking
Nice price action, starting to put its back into it.
In March / April I bought shares in Diamond Eagle (the SPAC for Draftkings).
Post vote approval there was a lift - I bought for $13 pre merger and ended up selling for $23 post merger - huge mistake.
I traded out when volumes were still high and ended up giving up about $25 a share - if I’d waited circa two months.
The volume (assuming positive reception) will be transformative here.
Hello folks,
Just trying to pull together a balanced view of risks.
What do we think are the potential biggest downsides? (I.e Tils)
Suspect rainbow chasers heading to avacta
Looks like a formality as the proposed close date is in January.
If the approval is granted they will need money to scale up production capacity - they could fund this through cash flow but would slow. roll out. I’m guessing we will get another placing before April/May. I think it’s positive as it’s all systems go with commercialisation.
It makes very little sense to sell this at such an early stage of commercialisation, you think for a derisked product they’d sell for 400-500 million?
Personally that seems fanciful, a rights issue seems likely to capitalise for scale up.